Q32 Bio has two targets in its sights: the two arms of the immune system.
The Cambridge, Mass., startup on Wednesday announced $46 million in Series A financing led by Atlas Venture, and disclosed it aims to address problems with both innate immunity, the body’s initial response to an invader, and adaptive immunity, which develops antibodies to the foreign interloper.
The biotech named the first drug in its pipeline, a monoclonal antibody that blocks interleukin 7 — a cytokine in the adaptive immune system — and revealed its plan to build fusion proteins that tamp down the activity of complement — a component of the innate immune system — in disease-affected tissues.
About the Author Reprints
